List view / Grid view
7 June 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Therapix Biosciences Ltd, have announced that the first subject was enrolled for its Phase IIa, a sponsor-initiated clinical trial for Obstructive Sleep Apnea...
21 May 2018 | By European Pharmaceutical Review
Cannabidiol was shown in a new large-scale, randomised, controlled trial to significantly reduce the number of dangerous seizures in patients with a severe form of epilepsy...
24 April 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers demonstrate hemp's ability to slow cancer growth and uncover mechanism for its cancer-fighting ability...
12 April 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
GB Sciences, Inc. is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies...
19 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers are calling for medicinal cannabis to be properly established in our modern medical arsenal...
8 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A naturally occurring compound found in cannabis may help to curb the frequency of epileptic seizures...
14 February 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers have found that cannabis therapy is safe and efficacious for elderly patients who are seeking to address cancer symptoms, Parkinson's disease, Crohn's disease and other medical issues...
25 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Treatment with a pharmaceutical formulation of cannabidiol alongside other anti-epilepsy treatments helped to reduce the number of drop seizures in people with Lennox-Gastaut syndrome...
7 September 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
Neuroscientists have found that cannabidiol reduces symptoms such as impaired memory in adolescent mice simultaneously exposed to THC...
28 July 2017 | By Steve Bremer (European Pharmaceutical Review)
Puration plans to displace pharmaceutical market leader, GW Pharmaceuticals, as part of strategy to grow US cannabis market
29 June 2017 | By European Pharmaceutical Review
A study has confirmed that cannabinoids are just as suitable as a prophylaxis for migraine attacks as other pharmaceutical treatments.
Send this to a friend
Follow: